Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc is a leading biotech firm that specializes in developing and commercializing innovative medicines to improve the lives of patients with gastrointestinal (GI) diseases and other conditions. Its flagship product, LINZESS, is a prescription medication that treats irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood has a robust pipeline of potential new therapies in various stages of development, including treatments for gastroesophageal reflux disease (GERD), abdominal pain associated with IBS, and other GI disorders. The company is dedicated to advancing science and delivering breakthrough therapies that address unmet medical needs, with a mission to make a meaningful difference in the lives of patients and their families.